1. Introduction {#sec1}
===============

Muscles form 45 and 35 percent of lean body mass in men and women, respectively. In the third decade of human life, a slow and progressive decrease of muscle mass and function in a large proportion of older individuals has been called sarcopenia [@bib1]. Sarcopenia accompanied by decreased mobility, physical disability, slow gait, and loss of independence which all lead to poor quality of life in older people. At the age of 65 years, nearly 5% of people and after 80 years approximately 50% of people may suffer sarcopenia [@bib2], [@bib3], [@bib4]. Rapid aging of Korea population in 2005, 2010 and 2015 which the people with age 65 and older respectively included 9.1%, 11% and 13.1% of the Korean population can show the importance of attention to sarcopenia [@bib5]. Age-related sarcopenia included skeletal muscle [@bib6], smooth muscle [@bib7] and cardiac muscle [@bib8]. Although sarcopenia definition is evolving [@bib9] but generally it is characterized by age-related muscle wasting. Apart from the aging, other factors such as autoimmune disorders, inflammatory disease, and endocrine dysfunction lead to sarcopenia [@bib10]. Myofiber atrophy, intramuscular fat accumulation, loss of motor unit, and fibrosis are several sarcopenia pathologies which are introduced as responsible for deficits of muscle function and mass [@bib11], [@bib12]. In addition, suppression of anabolic signaling, abnormal function of mitochondria in muscle cells, and apoptosis play role in pathogenesis of sarcopenia [@bib13], [@bib14].

Loss in the function and mass of muscular tissue can be caused by gradual decrease of circulating concentration of estrogens and androgens [@bib15]. For instance, men who received androgen deprivation therapy for prostate cancer showed declines in upper body muscle strength and function [@bib16]. On the other hand, post-pubertal growth and sexual dimorphism of muscles are influenced by sex steroid hormones including estrogens and androgens [@bib17]. Delineation of the current knowledge on how sex steroid hormones signals interact with controlling of the intracellular molecular pathways, may be useful for management of sarcopenia. This article reviews available information on the interaction between sex steroid hormones and muscles with a focus on the pathophysiology of sarcopenia from pre-clinical and clinical perspectives.

2. Sex steroid hormones effects on muscles {#sec2}
==========================================

Systemic hormones and load bearing have important roles in regeneration and hypertrophy after muscle injury [@bib18]. Anti- and pro-inflammatory cytokines, growth factors and sex steroid hormones are the major systemic hormones which influence muscle tissue function and mass [@bib19]. Role of sex steroid hormones on skeletal muscles includes i) regulation of muscle metabolic function, ii) increase of muscle strength, iii) maintenance and growth of muscle mass [@bib20], and iv) promotion of muscle repair after injury [@bib21]. Therefore, men and women muscle health can be implicated by decline of sex steroid hormones [@bib22] including decrease in mass and size of striated muscles [@bib22]. Estrogens and androgens have different effects on the function of muscle cells regarding the sex, muscle cell types and/or muscle anatomical position [@bib15].

Androgenic steroids including testosterone and mechanical loading increase skeletal muscle mass and growth in the normal males [@bib23], [@bib24], [@bib25] and females [@bib26]. Decrease in muscle size and strength is reported in the cancer patients [@bib27], [@bib28], individuals receiving androgen deprivation therapy such as prostate cancer patients as well as women in post-menopausal conditions [@bib22] and men suffered hypogonadism [@bib29]. In addition, premenopausal women with increased age experience decreases in androgens [@bib30]. Endogenous suppression of testosterone in aged men and women accounts for sarcopenia, muscle fat infiltration and decreased muscular quality in men more than the women [@bib11]. Low bioavailable testosterone associated with worse frailty status in the aged men [@bib31]. In the men with androgen deficiency [@bib25], [@bib32], [@bib33] and the castrated animal models [@bib34], [@bib35], it was reported that testosterone replacement therapy increased the strength and mass of muscle. Regarding to the effect of androgen and anatomical positions of skeletal muscle, muscles associated with copulation are more responsiveness to androgen than the weight bearing locomotive ones in male rat models [@bib35]. Furthermore, in androgen receptor knockout mice, the peripheral muscle mass and size was not different with wild type mice but the weight of levator ani was reduced in comparison with the wild type mice [@bib36].

Positive effects of estrogen replacement therapy including increase of muscle contractile function and post-exercise damage protection are shown in the ovariectomized rat models [@bib37], [@bib38], [@bib39], [@bib40]. In post-menopausal women conflicting findings after estrogen replacement therapy on muscular quality are demonstrated [@bib41], [@bib42], [@bib43]. Regarding to the effect of estrogen and locomotion function of skeletal muscle, in female mice, higher weight bearing muscles have more responsiveness to estrogens [@bib39]. Except skeletal muscles, the cardiac muscle [@bib44] and smooth muscles [@bib45] are more affected by estrogens. Furthermore, increase in body fat in males with estrogen deficiency is reported [@bib46].

A few studies evaluated the progesterone effects on skeletal muscle function and growth. Progesterone receptor presence is reported in skeletal muscle cells [@bib47] and some functions of this steroid hormone in skeletal muscle are evaluated. Skeletal muscle contractile characteristics were not affected by the fluctuations in progesterone levels throughout the menstrual cycle [@bib48]. Furthermore, treatment with progesterone has no effect on the capacity of skeletal muscle to oxidize lipids. However, by physiological concentrations\' treatment of ovariectomized rats with both estradiol and progesterone, progesterone inhibited the lipolytic effect of estradiol, and this was restored with pharmacological concentrations of estradiol [@bib49]. In addition, progestins may reduce proliferation of satellite cells in skeletal muscle of cow [@bib50]. Although the number of studies in comparison with the previous explained sex steroid hormones are low but some mechanisms are evaluated related to progesterone and skeletal muscle cell proliferation. In contrast, in smooth muscle cells, progesterone effects on cell proliferation, growth and function are more investigated. Both medroxyprogesterone acetate and etonogestrel reduce proliferation and migration of vascular smooth muscle cells [@bib51].

3. Sex steroid hormone receptors\' action in muscles {#sec3}
====================================================

Presence and activity of androgen receptor, estrogen receptor-α and --β and progesterone receptor are shown in different cell types of skeletal muscles ([Table 1](#tbl1){ref-type="table"}). Mesenchymal stem cells, satellite cells, myoblasts and myocytes express androgen receptors [@bib52], [@bib53], [@bib54]. Muscles are associated with reproduction express more androgen receptors than the weight bearing muscles and the receptors are more sensitive to androgens [@bib35]. Up-regulation of expression of androgen receptors in rodents and human muscle cells is done by both increase in androgen concentration [@bib21], [@bib35], [@bib55] and resistance trainings [@bib56], [@bib57], [@bib58], [@bib59]. On the other hand, in male mice with knocked out androgen receptor but not in females, muscle mass decreased [@bib60]. In specific androgen receptor knockout satellite cells in male mice [@bib61] and myocyte-specific androgen receptor knockout male mice [@bib36], mass reduction of highly androgen sensitive muscles has been reported whereas other peripheral muscles were not affected by specific androgen receptor delectation. Contrary to those findings, over expression of androgen receptor in transgenic rats increased muscle mass, hypertrophied myofibers, decreased adipocytes and increased oxidative metabolism [@bib62], [@bib63]. Furthermore, androgen receptors expression is detected in different types of smooth muscle tissues including vessels [@bib64], penis [@bib65], and myometrium [@bib66].Table 1Detected receptors of sex steroids on different cell types of skeletal muscle.Cell typesAndrogen receptorEstrogen receptor-αEstrogen receptor-βProgesterone receptorReferencesMesenchymal stem cells+NDNDND[@bib53]Satellite cells+++ND[@bib54], [@bib258]Myoblasts+++ND[@bib52], [@bib258]Myocytes++++[@bib47], [@bib52], [@bib73], [@bib258], [@bib259]Fibroblasts+++ND[@bib53], [@bib258][^1]

Satellite cells, myoblasts and myocytes express both estrogen receptor-α and -β in male and females [@bib67]. Expression pattern of estrogen receptors differ between sexes [@bib68]. However, deletion of estrogen receptor-β in female mice could not affect the muscle mass, but estrogen receptor-α knockout mice showed increase in muscle mass and decreased contractile properties [@bib39]. In comparison with wildtype in both sexes, knocking out of estrogen receptor-β improved the contractile properties and post damage recovery in male mice but not in females [@bib69]. In addition, expression of both types of estrogen receptors in smooth muscle cells have regulatory role in proliferation and differentiation of these cells [@bib70], [@bib71].

Although the presence progesterone receptors is detected [@bib72] in skeletal muscles, their role is not as clear as the other sex steroid hormone receptors. On the other hand, although the presence of progesterone receptor in myoblast cells are reported [@bib73], more investigations concerning to progesterone is necessary to confirm presence and absence of this type of sex steroid hormone receptor in other type of skeletal muscle cells. This despite the fact that numerous study clarified role of progesterone receptors in proliferation of smooth muscle cells of various tissues with inhibitory effects in vessels [@bib74] and stimulatory effects in myometrium [@bib75].

4. Sex steroid hormones and intracellular pathways in muscle cells {#sec4}
==================================================================

The role of sex steroid hormones in age-related changes in sarcopenia and alterations of intracellular signaling pathways in muscles is not well understood. Revealing the role of androgens and related receptors in increase of protein synthesis and skeletal muscle mass, understanding the molecular mechanisms that mediate these effects may help to develop supportive or even preventive therapy for the individuals suffering from sarcopenia. Muscle synthesis or degradation is regulated by several signaling pathways positively or negatively. Signaling pathways, paracrine mediators, and gene targets in the skeletal and smooth muscles which are regulated by androgens, estrogen and progesterone are summarized in [Table 2](#tbl2){ref-type="table"}.Table 2Recognized physiological effects of sex steroids on signaling pathways, paracrine mediators, and gene targets in the skeletal and smooth muscles.Signaling pathways/moleculesSkeletal muscleSmooth muscleAndrogenEstrogenProgesteroneAndrogenEstrogenProgesteroneAkt/mTORStimulation [@bib94]; inhibition [@bib88]Stimulation [@bib103], [@bib106]NDStimulation [@bib95]Stimulation [@bib108], [@bib260]Inhibition [@bib110], [@bib143]FoxO3Inhibition [@bib88], [@bib119]; no effect [@bib120]No effect [@bib120]; stimulation [@bib106]No effect [@bib120]ND^a^NDNDMAPK1/3 (ERK1/2)Stimulation [@bib135]No effect [@bib103]; stimulation [@bib139]NDStimulation [@bib137]stimulation [@bib140], [@bib142]Stimulation [@bib114], [@bib142], [@bib143]WntStimulation [@bib149]NDNDNDStimulation [@bib157]Stimulation [@bib157]NotchStimulation [@bib152]; inhibition [@bib149]NDNDNo effect [@bib261]NDNDNF-κBInhibition [@bib166], [@bib169]NDNDInhibition [@bib170]Inhibition [@bib171], [@bib262]Inhibition [@bib175]; stimulation [@bib143]TNF-αNDInhibition [@bib188]NDInhibition [@bib170]Inhibition [@bib190]Inhibition [@bib176], [@bib192]InterleukinsInhibition [@bib88]Stimulation [@bib188]; no effect [@bib263]Inhibition [@bib192]Inhibition [@bib186]No effect [@bib264]; inhibition [@bib265]Inhibition [@bib193]; no effect [@bib175]MRF (MyoD and myogenin)Inhibition [@bib119]; no effect [@bib266]Stimulation [@bib203]; Inhibition [@bib202]Stimulation [@bib50], [@bib120]ND^b^NDNDCDKStimulation [@bib154]NDNDInhibition [@bib212]Inhibition [@bib217]Inhibition [@bib112], [@bib143]Myostatin/AcIIb/ActivinInhibition [@bib224], [@bib267]; no effect [@bib120]No effect [@bib120]No effect [@bib120]ND^c^Inhibition [@bib227]Inhibition [@bib227][^2][^3]

4.1. IGF-I/Akt/mTOR pathway {#sec4.1}
---------------------------

One of the pathways which is controlled by androgenic signals and has critical role in survival and growth of muscles via protein synthesis is the insulin growth factor-1 (IGF-I)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway ([Fig. 1](#fig1){ref-type="fig"}A) [@bib76], [@bib77]. Aging and inflammation can impede activation of muscle mTOR signaling [@bib78]. Protein synthesis enhanced by phosphorylation of 4E-BP1 and p70S6K which are subsequent of activated mTOR by Akt [@bib79]. Also, Akt can inhibit glycogen synthase kinase-3 beta (GSK3β) which is the inhibitor of protein synthesis [@bib80]. On the other hand, two isoforms of IGF-I which synthesized in muscle tissue, mechano growth factor (MGF or IGF-IEc) and the IGF-I which is similar to the ones which is synthesized by liver, have auto- and paracrine effects [@bib81]. IGF-I is increased by mechanical loading and testosterone by the activation of Akt and androgen receptors have critical role in IGF-I synthesis in myocytes [@bib82]. Reduction in intramuscular IGF-I synthesis and circulating IGF-I is associated with deficiency of androgens in men [@bib29], [@bib83] or castrated rodents [@bib84], [@bib85]. On the other hand, androgen replacement in castrated rodents increased muscle performance without increase in muscle fiber growth or activation of the Akt/mTOR pathway [@bib86]. Additionally, testosterone induced IGF-I/Akt pathway by increasing expression of IGF-I mRNA and glycogen synthase kinase 3β (GSK3β) phosphorylation in female rats [@bib87]. Ambiguous findings are present on the effect of testosterone supplementation or castration on Akt activation in the skeletal muscles [@bib85], [@bib86], [@bib88]. Differences in the type of muscles were examined as well as dose of androgen, type and duration of testosterone deficiency may exhibit the variability in the experimental findings on sensitivity of androgens on IGF-I/Akt/mTOR pathway in skeletal muscle.Fig. 1Schematic diagram of (A) androgen and (B) estrogen effects on AKT/mTOR and FoxO signaling in skeletal muscle cells. Abbreviations: Akt, serine/threonine-specific protein kinase; AMPK, 5′-adenosine monophosphate-activated protein kinase FoxO, Forkhead box O; GSK3β, glycogen synthase kinase 3β; IGF-I, insulin growth factor-I; MHC, myosin heavy chain; mTOR, mechanistic target of rapamycin; T2, testosterone.Fig. 2Schematic diagram of androgen effects on mitogen-activated protein kinase (MAPK) signaling in skeletal muscle cells. Abbreviations: ERK1/2, extracellular-signal-regulated kinases 1/2; MAPK1/3, mitogen-activated protein kinase 1/3; MEF2, myocyte enhancer factor-2; MRF4, myogenic regulating factor 4; SWI/SNF, SWItch/sucrose non-fermentable.

The other pathway can occur independent of activation of upstream Akt is the mammalian target of rapamycin complex 1 (mTORC1) which its activation regulates several cellular process such as protein synthesis [@bib89], [@bib90]. Testosterone induced increases in protein synthesis can be blocked by rapamycin, the mTORC1 inhibitor, in myotubes [@bib91] ([Fig. 1](#fig1){ref-type="fig"}A). The mTORC1 repressors includes proline-rich Akt substrate-40 (PRAS40), mammalian lethal with SEC13 protein 8 (mLST8), and 5\'-adenosine monophosphate-activated protein kinase (AMPK) [@bib92], [@bib93]. Synthesis of muscle myofibrillar protein decreased by androgen withdrawal through Akt/mTORC1 pathway and was independent of activation of AMPK and reversed by testosterone administration [@bib94]. Low dose of testosterone activate mTOR pathway independent of Akt; while, high dose testosterone activated Akt pathway in skeletal muscle fibers [@bib94]. In smooth muscles, same evidences of stimulatory effect of androgen on Akt pathway are reported [@bib95], [@bib96].

Estradiol induces the Akt phosphorylation in myoblasts ([Fig. 1](#fig1){ref-type="fig"}B) [@bib97]. Decrease in muscle Akt phosphorylation which is induced by estrogen deficiency in ovariectomized rats caused decrease in muscle mass [@bib98]. On the other hand, expression of IGF-I receptor in skeletal muscle cells increased in post-menopausal women after estrogen replacement while expressions of miRNAs such as miR-182, miR-223 and miR-142-3p decreased [@bib99]. Considering the skeletal muscle glucose metabolism, activation of AMPK was suppressed in ovariectomized mice, but estradiol injection reverse it [@bib100]. In addition, in skeletal muscles, Akt/mTOR pathway is inhibited by AMPK activation [@bib101], [@bib102]. Estradiol also increases translocation of glucose transporter, Glut-4 to the plasma membrane through Akt pathway and cause increase of myogenin and myosin heavy chain (MHC) which are important in morphological appearance of skeletal muscles [@bib103], [@bib104], [@bib105]. Estradiol administration in postmenopausal women induced up-regulation of expression of mTOR genes [@bib106]. Furthermore, in smooth muscle cells, IGF-I-stimulated phosphoinosotide-3-kinase (PI3K) pathway up-regulation is inhibited by increase in AMPK activation [@bib107]. Estrogen induce smooth muscle acute response through the PI3-kinase/Akt signaling axis [@bib108]. In uterine smooth muscles, estradiol up-regulates of the amount of p-mTOR in rat [@bib109].

A limited number of investigations studying the effects of progesterone on the skeletal muscle cells, to the best of our knowledge, none evaluating this steroid effect on the IGF-I/Akt/mTOR pathway in the skeletal muscle cells. On the other hand, progesterone down-regulates key components of the mTOR pathway in myometrium [@bib110]. Also, progesterone inhibits proliferation and migration of smooth muscle cells [@bib74], [@bib111], [@bib112] by induction of p27 up-regulation through the progesterone/cSrc/AKT/ERK 2/p38-mediated signaling pathway [@bib113], [@bib114].

4.2. FoxO family {#sec4.2}
----------------

Akt inhibits protein degradation by the phosphorylation of transcription factors in forkhead box O (FoxO) family [@bib115] ([Fig. 1](#fig1){ref-type="fig"}A). FoxO1 and 3 activated in muscle atrophy conditions in skeletal muscles [@bib19], [@bib116]. Testosterone down-regulates transcription of FoxO-related genes and expression of FoxO in skeletal muscle to inhibit muscle catabolism [@bib85], [@bib88], [@bib117], while castration increased them [@bib85]. In addition, testosterone can prevent dexamethasone-induced atrophy of skeletal muscle by blocking the expression of FoxO1 gene [@bib118]. Suppression of FoxO family by androgen resulted in myogenin/ubiquitin ligase-mediated atrophy pathways and preserve muscle mass [@bib119]. In postmenopausal women skeletal muscle, expression of FoxO3 mRNA is greater than premenopausal [@bib120]. However, testosterone replacement therapy had no effects on the FoxO3 mRNA expression in postmenopausal women [@bib120]. This different finding in postmenopausal women with previous investigations in rodent may related to aging effect on the inhibitory effects of androgen and its receptor with FoxO family and needs more investigation. On the other hand, although FoxO3 is detected in smooth muscle cells [@bib121] but the effect of androgens on this molecular pathway has not been investigated yet.

The effect of estradiol on the FoxO family in skeletal muscle is controversial. However, it is shown that estradiol treatment had no effect on mRNA expression of FoxO3 in skeletal muscle [@bib120], but it is also shown that estradiol treatment of postmenopausal women caused up-regulation of both FoxO3 and FoxO1 in the skeletal muscles ([Fig. 1](#fig1){ref-type="fig"}B) [@bib106]. On the other hand, although FoxO3 is detected in smooth muscle [@bib121] but there is no information on the effects of estrogens on the FoxO3.

Progesterone treatment had no effect on FOXO3 mRNA expression in skeletal muscle of premenopausal and postmenopausal women [@bib120]. Although FoxO3 is detected in smooth muscles [@bib121], but there is no data on the effect of progesterone on FoxO3.

4.3. MAPK pathway {#sec4.3}
-----------------

In the intracellular signal pathway, mitogen-activated protein kinases (MAPK) regulate muscle growth through i) SWItch/sucrose non-fermentable (SWI/SNF) complex recruitment for activation of muscle cell differentiation promoters [@bib122], ii) by E47 E-box protein phosphorylation to enhance transcriptional activity of MyoD and myocyte enhancer factor-2 (MEF2)A, -C, and -D factors [@bib104], [@bib123], [@bib124], and iii) phosphorylation of myogenic regulating factor 4 (MRF4) to inhibit it to facilitate myogenesis [@bib125], [@bib126] ([Fig. 2](#fig2){ref-type="fig"}). Extracellular-signal-regulated kinases 1/2 (ERK1/2), which are classical MAPK, have role in differentiation, division, growth in skeletal muscle cells. Their activation is enhanced by growth factors [@bib127], exercises [@bib128], diverse stress stimuli [@bib129], and hormones [@bib130], [@bib131]. Chronic inflammation induces p38 and ERK1/2 signaling which leads to muscle wasting [@bib132], [@bib133]. Steroid hormones increased skeletal muscle cell calcium release from their reservoirs and simultaneously activate MAPK pathways [@bib134]. It is also shown that testosterone could activate ERK1/2 pathway in skeletal muscle [@bib135]. In smooth muscle cells testosterone had biphasic stimulatory and inhibitory effects in low and high concentration, respectively [@bib136]. It is also shown in the both dose dependent effects of testosterone, stimulation or inhibition of MAPK pathway had role in regulation of smooth muscle cell proliferation [@bib137]. Therefore, more investigations are necessary to clarify the MAPK pathway role in the androgen deficient sarcopenia patients or androgen supplementation in sarcopenia animal models.

The effects of estrogen on ERK/MAPK signaling in muscle cell differentiation is controversial [@bib131], [@bib138]. It is shown that ERK1/2 does not have role in muscle differentiation by estradiol [@bib103]. In contrast, it is reported that ERK1/2 is activated by estradiol in skeletal muscle cells under differentiation conditions [@bib139]. Estradiol induces the expression of myogenin and MHC in skeletal muscle by phosphorylation p38 [@bib103]. Therefore, to clarify the role of MAPK pathway in skeletal muscle differentiation further investigation can be performed. On the other hand in smooth muscle, estradiol inhibits proliferation and migration of the cells via reversing phosphorylation of p42/44 and p38 MAPK and through estradiol receptors [@bib140], [@bib141]. In contrast to reduce myogenic tone of smooth muscle in pregnant uterus, estradiol has a direct chronic effect in the up-regulation of ERK1/2 expression [@bib142].

No investigations evaluated the progesterone effects on the MAPK pathway in the skeletal muscle cells. On the other hand, progesterone increased ERK1/2 protein in smooth muscle cells [@bib142]. It is also shown that in smooth muscle cells, progesterone inhibited cell proliferation by activating the cSrc/Kras/Raf-1/AKT/ERK/p38/IκBα/NFκB pathway up-regulates the expression of p21^cip1^ and p27^kip1^ through increasing the level of p53 protein [@bib114], [@bib143].

4.4. Wnt and Notch signaling {#sec4.4}
----------------------------

Wnt signaling stimulates the formation and differentiation of skeletal muscle in embryo [@bib144], [@bib145]. Activation of Myf5 (for Wnt1), MyoD (in the case of Wnt7a), or receptor Fzd7 (by Wnt7a) are the regenerative effects of Wnt signaling pathway in skeletal muscles [@bib146], [@bib147]. In addition, Wnt signaling decrease the inhibitory effect of Notch signaling to increase the differentiation of muscles via promoting the myogenic progenitors [@bib148]. Androgen increased Wnt signaling via up-regulation of Numb in myoblasts [@bib149]. Also, nandrolone, an anabolic androgen, activated Wnt-dependent up-regulation of Numb and resultant reduced Notch signaling during differentiation of muscle progenitor cells [@bib149]. Furthermore, it is also shown that nandrolone diminished mdm2 levels to stabilize Numb protein in myoblasts [@bib150]. Also, up-regulation of Numb by nandrolone in denervated muscle reduced Notch signaling [@bib151]. Although some studies showed that indirectly and via the Wnt pathway androgens decreased the Notch signaling, but testosterone in murine muscles increased expression of Notch 1, Notch 2 and Delta 1 [@bib152]. In addition, in older man satellite cells, testosterone increased Notch expression [@bib153]. Furthermore, in aged skeletal muscle of mice, testosterone induced expression of Notch 1 receptor [@bib154]. All these findings demonstrate the up-regulatory effect of testosterone on Notch signaling and skeletal muscle cell proliferation. Thus, the Wnt signaling and the Notch signaling are the other pathways which is stimulated by androgens to promote proliferation and then differentiation of skeletal muscle cells. On the other hand, although Wnt signaling pathway is described in smooth muscle cells [@bib155] but the effect of androgens on this molecular pathway has not been investigated yet.

There is no information regarding the effects of estradiol on Wnt and Notch signaling in skeletal muscle, but it is shown that estradiol in combination with trenbolone acetate increase the expression of WISP2 (Wnt-1 inducible signaling pathway protein 2) in sheep skeletal muscle [@bib156]. In smooth muscle, Estradiol administration induces secretion of WNT11 and WNT16, WNT ligands, from mouse myometrial cells which express estrogen receptor α [@bib157]. In both smooth and skeletal muscle, the effect of estradiol on notch signaling is not clarified.

Studies on the progesterone effects via Wnt and Notch signaling in skeletal and smooth muscles are not available. There is only a study in smooth muscle myometrial cells which showed progesterone in combination with estrogen induces WNT ligands secretion [@bib157].

### 4.4.1. NF-κB pathway {#sec4.4.1}

Skeletal myogenesis inhibition is enhanced by nuclear factor-κB (NF-κB) pathway activation [@bib158]. The TNF-α and proteolysis-inducing factor (PIF) are the cytokines which activate NF-κB to induce proteolysis and apoptosis in skeletal muscles [@bib159], [@bib160], [@bib161], [@bib162], [@bib163]. Stimulation of inflammatory pathways which activate NF-κB in sarcopenia leads to acute or gradual muscle wasting [@bib164], [@bib165]. NF-κB induces skeletal muscle atrophy by pro-inflammatory cytokines through downstream signaling requiring RelA/p65 [@bib164]. In a normal skeletal muscle an upstream NF-κB pathway activating kinase, NF-κB--inducing kinase (NIK), maintains at low basal levels [@bib166]. Stimulation of NF-κB noncanonical pathway leads to cIAP1/2 degrades and ubiquitinates TRAF3. TRAF3 releases and stabilizes NIK and causes NIK accumulation in cells [@bib167], [@bib168]. There is an association between aging and accumulation of NIK in skeletal muscles in older men [@bib166]. Activation of NF-κB pathway by increase of NIK levels leads to catabolism of muscle proteins and sarcopenia progression. Testosterone supplementation can decrease NIK content in skeletal muscle of older men [@bib166]. In addition, simultaneous testosterone and protein supplementation suppressed p52 and RelB expression in skeletal muscle of women [@bib169]. In older women, suppressive effect of androgen administration on NF-κB pathway for prevention of women sarcopenia is not clarified. In contrast to the describe catabolic role of NF-κB in skeletal muscles, a canonical p50/RelA pathway and non-canonical p52/RelB pathway in the other model of NF-κB signaling in skeletal muscle suggests these pathway effects in myogenesis [@bib158]. On the other hand, same inhibitory effect of androgens on smooth muscle degradation through suppression of NF-κB is also reported. IκB-α degradation and the LPS-induced NF-κB nuclear translocation were prevented by testosterone in rat smooth muscle of prostate [@bib170].

However, NF-κB pathway is described in skeletal muscle cells [@bib158] but there is no data on the effects of estrogens on the NF-κB pathway in these cells. In contrast, in smooth muscle cells, gene transfer of estrogen receptor-α and estradiol treatment inhibited NF-κB activation and induced cell proliferation in aged rat [@bib171]. In the rat uterus, estradiol treatment also inhibited NOS II induction, which its promoter region contains NF-κB binding sites [@bib172], [@bib173]. Thus it can be postulated that in postmenopausal women, decrease in expression of functional estrogen receptor-α number and/or decrease in estradiol levels activate NF-κB, but experiments will be needed to clarify this subject both in smooth and skeletal muscles.

Such as the previous mentioned pathways, progesterone effect on this pathway in skeletal muscle also is not investigated. However, investigations on this subject in smooth muscle cells are available. It is shown that myometrium beside the infiltrated inflammatory cells is a major source of inflammatory cytokines [@bib174]. Functional progesterone withdrawal during parturition activates NF-κB in myometrium through progesterone receptors [@bib175]. Also, expression of progesterone receptors is down-regulated by IL-1β and TNF-α in myometrial smooth muscle cells [@bib175], [@bib176]. Therefore, these both mechanisms can activate NF-κB in smooth muscles by decreasing the progesterone effect in myometrium. In contrast, it is shown that in vascular smooth muscle cells progesterone increases both the formation of progesterone receptor-NFκB complex in the nucleus and the binding of progesterone receptor onto the NFκB binding fragment of the p53 promoter [@bib143]. Therefore, in vascular smooth muscle cells activation of NF-κB is involved in the progesterone-induced up-regulation of p27 [@bib143]. These controversies may be related to the cell types or species which are evaluated in these studies and need to be more investigated.

### 4.4.2. Interleukins and tumor necrosis factor {#sec4.4.2}

Proinflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 increase by androgen deficiency in both experimental and clinical studies [@bib177], [@bib178]; while, decrease after androgen replacement therapy [@bib179]. Muscle mass and strength in elderly peoples inversely related to interlukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) concentrations [@bib180]. Furthermore, protein breakdown of rat skeletal muscle is increased by the administration of IL-6 [@bib181] or TNF-α [@bib182]. Production of IL-6 has been increased by activation of p50/RelA [@bib183]. In cancer cachexia, gradual chronic increase of IL-6 and absence of increased TNF-α in this catabolic diseases are reported [@bib184]. It is also shown that following exercise, IL-6 is up-regulated in skeletal muscle [@bib185]. Castration of mice induced increasing of IL-1α and decreasing of interferon-γ (IFNγ) and simultaneously levator ani muscle atrophy, however testosterone could prevent these side effects by down-regulation of IL-1α and up-regulation of IFNγ expressions [@bib88]. On the other hand, although effect of TNF-α is described in skeletal muscle cells but the effect of androgens on this cytokine has not been clarified. In the smooth muscle, at subphysiological testosterone, levels TNF-α, IL-2, IL-6, IL-10, IL-12, and IL-13 were elevated [@bib186].

After muscle injury, TNF-α expression increased within 24 h and the increase was higher in ovariectomized rats [@bib187], [@bib188]. Estradiol reduced TNF-α expression during regeneration of skeletal muscle via estrogen receptor-β but not estrogen receptor-α and also promote expression of IL-10 [@bib188].

It is also shown that estrogen treatment of male subjects before acute eccentric exercise decreased neutrophil infiltration in skeletal muscle [@bib189]. In smooth muscle cells, expression of cytokine-induced neutrophil chemoattractant-2β is inhibited by treatment with selective agonist of estrogen receptor-β and also TNF-α-treated smooth muscle cells chemotactic activity was reduced [@bib190].

Probable role of progesterone in regulation of these factors in skeletal muscles are unclear. Although it is demonstrated that megestrol acetate, a synthetic progestin, reduced both skeletal muscle size and serum IL-6 [@bib191], [@bib192]. In smooth muscles this role is partially defined. Although, progesterone receptor does not play a role in down-regulation of pro-inflammatory gene networks induced by IL-1β [@bib175], but IL-1α is decreased by progesterone through decreasing the stability of IL-1α mRNA by stimulating the production of an intracellular intermediate [@bib193]. Therefore, it can be claimed that in both skeletal and smooth muscles, progesterone inhibit production of inflammatory cytokines.

### 4.4.3. Myogenic regulating factors {#sec4.4.3}

Muscle development and growth is controlled by the myogenic regulatory factors (MRFs) including myogenin, MyoD1, Myf5, and Myf6 [@bib194]. Myogenesis can be inhibited by notch signaling through the repressing the MyoD [@bib195], as well as by biding directly to MEF-2C [@bib196]. Androgens repressed myogenin which regulates the myoblasts transition from the proliferative state to the terminally differentiated myocytes [@bib119], [@bib197]. The androgen maintains proliferation of myoblasts by delaying myotube formation [@bib119]. In contrast with these findings, it is shown that testosterone via enhancement of androgen receptors may increase myogenin in mouse myoblast cell line [@bib198]. While, dihydrotestosterone had no effects on expression of myogenin in human skeletal muscle cells (SkMC) as well as in in-vivo conditions in orchiectomy and androgen receptor knockout mice and also in other MRF including MyoD1, Myf5, and Myf [@bib119]. On the other hand, in in-vivo conditions myogenin repressed by androgen/androgen receptor pathway [@bib119]. Regarding, SkMC may not be an appropriate model for in-vitro evaluation of proliferation of myocytes, despite the fact that expression level of androgen receptors in SkMC is similar to in-vivo muscle cells [@bib199]. Expression levels of myogenin decreased concomitant with increase in age and testosterone level in male mice [@bib200]. The variation of in-vitro methods or even cell lines may result difference findings and evaluation of other kinds of in-vitro and in-vivo models will be necessary to clarify the effects of androgens on MRF. Furthermore, although MRF are detected in smooth muscle cells [@bib201] but the effect of androgens on this molecular pathway has not been investigated yet.

The effects of estrogens on myogenic regulating factors are controversies. For instance the overexpression of exogenous ERα in the presence of E2 decreased the expressions of myogenin [@bib202]. While, knockdown of ERβ reduced myogenin level in the presence or absence of estradiol [@bib202]. It is shown that estradiol can induce expression of USP19 and with the above mentioned mechanism can repress myotube formation [@bib202]. On the other hand, estradiol induced expression of MyoD mRNA in males to the levels found in females [@bib203]. Therefore, further studies may clarify the role of estrogens in regulation of myogenic regulating factors in male and female skeletal muscles. In the smooth muscles, although myogenic regulating factors are detected [@bib201] but the effect of estrogens on them are not available.

MYOD1 expression is increased by progesterone which resulted in satellite cell activation in postmenopausal women skeletal muscle cells [@bib120]. In addition, progesterone and megestrol acetate increased myogenin mRNA expression 2.5 times in bovine satellite cells and C2C12 cultures [@bib50]. In smooth muscle cells no data is available related to the effect of progesterone on myogenic regulating factors.

4.5. Cyclin-dependent kinase {#sec4.5}
----------------------------

Cyclin-dependent kinases (CDKs) are protein kinases family and are involved in regulating the cell cycle, mRNA processing, transcription, and the differentiation of cells. Increasing age is related to the induction of CDK inhibitors through Notch pathway [@bib204]. It is shown that p21, a CDK inhibitor [@bib205], interferes regeneration of satellite cells [@bib206], [@bib207], [@bib208]. p21 expression increase is observed in mice concomitant with the increase of age [@bib154]. Furthermore, this age-associated increase in expression of p21 was reversed by testosterone administration [@bib154]. On the other hand, inhibition of c-jun NH~2~-terminal kinase (JNK) by testosterone could cause apoptosis suppression of muscle cells and increasing of muscle fiber growth [@bib154]. Suppression of JNK and up-regulation of p21 could induce muscle cell proliferation [@bib209], [@bib210]. In androgen receptor knockout mice, expression of the Cdkn1c (p57^Kip2^), a cell cycle regulatory gene, increased [@bib60] which has role in decreasing myoblast proliferation and increasing myoblast cell cycle exit and differentiation [@bib211]. Therefore, in part via the androgen receptors/CDK pathway, the proliferative effect of androgens in skeletal muscle may be performed. On the other hand, in smooth muscles, testosterone inhibited activity of CDK2 and CDK6 [@bib212]. CDK2 activity has role in transition of cells from G1 to S [@bib213]. It is also shown that testosterone can block CDK2 in smooth muscles through activation of CDK inhibitors p21^cip11^ and p27^kip1^ [@bib214], [@bib215], [@bib216].

However, no data was found that directly show the effect of estrogens on cyclin-dependent kinase in skeletal muscle cells but this phenomenon is defined to a certain extent. A metabolite of estradiol with no affinity for estrogen receptors, 2-Methoxyestradiol, arrests proliferating smooth muscle cells by inhibition of cyclin D1 and B1 expression and cdk1 and cdk4 activity and up-regulation of the expression of the cdk inhibitor p27 [@bib217]. It is also shown that estradiol exert an antiproliferative effect in smooth muscle cells through the inhibition of the cyclin D1 promoter activity in transfected with cDNA for estrogen receptor-α [@bib218]. In contrast, in uterine smooth muscle cells, estradiol-induced overproliferation was accompanied by and up-regulation of cyclin-dependent kinases and cyclin D1, cyclin E1, CDK2, CDK4, and CDK6 and down-regulation of cyclin-dependent kinases inhibitors [@bib219]. Therefore, the effect of estrogens on cyclin-dependent kinase depends on the origin of smooth muscle cells.

Based on our knowledge, role of progesterone in cyclin-dependent kinase regulation in skeletal muscles is not explained. However, in smooth muscle cells, cyclin-dependent kinase system is inhibited by progesterone via increase of cyclin-dependent kinase-inhibitors, p21^cip1^ and p27^kip1^ [@bib112], [@bib143].

4.6. Myostatin {#sec4.6}
--------------

Myocytes produce myostatin or growth differentiation factor 8 which has an inhibitory autocrine action on muscle cell differentiation and growth [@bib220]. By suppressing the MyoD activity, myostatin induces double muscled phenotype [@bib221], [@bib222], [@bib223]. Myostatin mRNA expression was suppressed by testosterone in adult skeletal muscle of castrated rats [@bib224]. It is shown that there is androgen response element (ARE) in the myostatin promoter [@bib225]. The myostatin Knockout mice failed to produce myotubes which is related to silencing of Actc1, Acta1, and MyoD [@bib226]. In contrast in women, myostatin mRNA expression after testosterone administration was not different in premenopausal and postmenopausal women [@bib120]. Therefore, to clarify the effect of testosterone on expression of mysostatin in female skeletal muscles, further investigations are necessary. Furthermore, although myostatin is detected in smooth muscle cells of uterus [@bib227] but the effect of androgens on this protein in myometrial cells has not been clarified.

Estradiol treatment had no effect on myostatin mRNA expression in skeletal muscle of premenopausal and postmenopausal women [@bib120]. In contrast, in uterine smooth muscle cells of ovariectomized rats, myostatin expression increased estrogen treatment decreased myostatin expression [@bib227].

In skeletal muscle cells, progesterone treatment had no effect on mRNA expression of myostatin in postmenopausal women [@bib120]. On the other hand, in smooth muscle cells of myometrium of rat uterus, myostatin expression is weakly decreased by progesterone [@bib227].

5. Sex steroid hormones therapy for sarcopenia {#sec5}
==============================================

It is remains unknown whether the several mechanisms responsible for sarcopenia discussed above can be controlled by a single therapeutic intervention which leads to rescue of muscle function and mass in old age. Furthermore, for the treatment or prevention of sarcopenia a FDA approved modalities is not still present. On the other hand, limited efficiency of current pharmacologic interventions and lack of standardized primary outcome of anti-sarcopenia drugs are some difficulties in developing therapeutic interventions [@bib228]. By the way, based on the mechanisms of the effects of sex steroid hormones, androgens, estrogens and progestogens several therapeutic agents for treatment of sarcopenia can be discussed.

5.1. Androgens-related therapeutics {#sec5.1}
-----------------------------------

In castrated aged mice, early indices of muscle regeneration are improved by testosterone supplementation [@bib229]. In men, 300 to 1000 ng/dl (10.4 to 34.7 nmol/L) testosterone in serum is considered as normal and low concentrations is ≤ 300 ng/dl (10.4 nmol/L) testosterone and frank hypogonadism will be ≤ 250 ng/dl (8.7 nmol/L) testosterone [@bib230]. Testosterone supplementation with low or low-normal levels in men aged older than 45 years increase muscle mass and strength [@bib231], [@bib232]. In adult man, testosterone therapy has no effect on prostate, cardiovascular outcomes and even mortality, but its adverse effect including decrease in high-density lipoprotein cholesterol and increase in hemoglobin and hematocrit is reported [@bib233]. In addition, increased risk of cardiovascular adverse events, edema and worsening of sleep apnea were observed in older men who were administrated testosterone gel [@bib230], [@bib234]. Sarcopenic elderly men most frequently administered by intramuscular injection of long-acting testosterone esters such as testosterone enanthate or testosterone cypionate at a dose between 50 and 400 mg every 2--4 weeks [@bib235]. Also, transdermal administration via patch or gel (1%, once daily between 50 and 100 mg) preparations and infrequently via oral administration are reported [@bib230].

Dehydroepiandrosterone (DHEA) displays androgenic signaling in muscle cells by binding androgen receptors. Benefit of DHEA supplementation in muscle strength or body composition in older men and women remains inconclusive [@bib236], [@bib237]. On the other hand, DHEA in combination with exercise improved physical strength in frailer adults [@bib179], [@bib238]. Nandrolone (19-nortestosterone) is an anabolic steroid which through activation of Notch signaling reduces muscle atrophy in sarcopenia rat model [@bib151]. Furthermore, administration oxandrolone in combination with progressive resistance training improved body composition in elderly women [@bib239]. In addition, non-steroidal selective androgen receptor modulators (SARMs) represent therapeutics for the treatment of sarcopenia. Different SARMs including GLPG0492 [@bib240], andarine [@bib241], NEP28 [@bib242], enobosarm [@bib243], [@bib244], [@bib245], MK-0773 [@bib246], and LGD2941 [@bib247] are showed to have beneficial effects on improvement of muscle mass. Therefore, further clinical trials are necessary to evaluate effects of supplementation with testosterones, DHEA, nandrolone, oxandrolone, and SARMs on elderly sarcopenic patients.

5.2. Estrogens-related therapeutics {#sec5.2}
-----------------------------------

A meta-analysis showed that hormone therapy of postmenopausal women with estrogen approximately 5% increase strength of muscle [@bib248]. Furthermore, risks of stroke, coronary heart disease, breast and skin cancer, and pulmonary embolism increased in postmenopausal women after use of combination of estrogen and progestin [@bib249], [@bib250], [@bib251]. Therefore, for preventing or treating of sarcopenia in postmenopausal women estrogen therapy is not recommended.

5.3. Progestogens-related therapeutics {#sec5.3}
--------------------------------------

Study shows directly the therapeutic effect of progestogens on sarcopenia is not available. In menopausal women, progesterone administration (100 mg/d by using a vaginal insert) improved muscle protein synthesis [@bib120]. In elderly persons, progestin such as megestrol acetate increases weight gain [@bib252], [@bib253]. On the other hand, oral bioidentical progesterone is safer and more efficient than synthetic progestins. Bioidentical progesterone cardiovascular safety [@bib252], [@bib254] even in combination with transdermal estradiol [@bib255] and also lower risk of breast cancer [@bib256], [@bib257] is better than synthetic progestins.

6. Conclusions {#sec6}
==============

Further studies are needed to clarify the exact effects of sex steroid hormones on the different types of muscle cells and their interaction with the molecular pathways controlling processes of apoptosis, proliferation and differentiation; but the current knowledge on these signaling pathways may help develop new therapeutics targeting the specifically related receptors on skeletal or muscle cells. As have been discussed, management of sarcopenia and improvement of muscle mass condition or control of this tissue wasting needs a wide range of studies that cover basic to clinical investigations.
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[^1]: ND: there is no available data.

[^2]: ND: there is no available data, although ^a^FoxO3 [@bib121], ^b^CRFs [@bib201] and ^c^myostatin [@bib227] are detected in smooth muscles.

[^3]: Akt, serine/threonine-specific protein kinase; CDK, cyclin-dependent kinase; ERK1/2, extracellular-signal-regulated kinases 1/2; FoxO3, Forkhead box O3; MAPK1/3, mitogen-activated protein kinase 1/3; MRF, myogenic regulating factors; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor-κB; TNF-α, Tumor necrosis factor.
